First Light Asset Management LLC Lowers Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

First Light Asset Management LLC cut its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 17.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 779,158 shares of the biotechnology company’s stock after selling 164,952 shares during the quarter. AnaptysBio accounts for 1.7% of First Light Asset Management LLC’s holdings, making the stock its 27th largest holding. First Light Asset Management LLC owned approximately 2.85% of AnaptysBio worth $19,526,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ANAB. Fisher Asset Management LLC grew its position in AnaptysBio by 0.7% in the 4th quarter. Fisher Asset Management LLC now owns 71,154 shares of the biotechnology company’s stock valued at $1,524,000 after acquiring an additional 500 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of AnaptysBio by 1.8% in the second quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock valued at $745,000 after purchasing an additional 525 shares during the period. Allspring Global Investments Holdings LLC purchased a new stake in AnaptysBio during the 1st quarter worth approximately $38,000. China Universal Asset Management Co. Ltd. lifted its holdings in AnaptysBio by 66.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock worth $115,000 after buying an additional 2,051 shares in the last quarter. Finally, Headlands Technologies LLC boosted its position in AnaptysBio by 444.8% in the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 2,900 shares during the period.

AnaptysBio Trading Down 7.6 %

Shares of AnaptysBio stock opened at $35.57 on Tuesday. The company has a fifty day simple moving average of $35.79 and a 200-day simple moving average of $27.95. The stock has a market cap of $971.74 million, a price-to-earnings ratio of -5.79 and a beta of -0.29. AnaptysBio, Inc. has a 12-month low of $13.36 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The firm had revenue of $10.97 million for the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. On average, analysts forecast that AnaptysBio, Inc. will post -6.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

ANAB has been the subject of a number of recent research reports. Truist Financial lifted their target price on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, August 15th. JPMorgan Chase & Co. upped their target price on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of AnaptysBio in a research note on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, AnaptysBio currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.30.

Insider Transactions at AnaptysBio

In related news, Director Hollings Renton sold 10,000 shares of the company’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $30.64, for a total value of $306,400.00. Following the completion of the sale, the director now owns 1,950 shares in the company, valued at approximately $59,748. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, Director Hollings Renton sold 10,000 shares of the business’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $30.64, for a total value of $306,400.00. Following the transaction, the director now owns 1,950 shares in the company, valued at approximately $59,748. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $35.00, for a total value of $52,500.00. Following the sale, the insider now directly owns 11,618 shares of the company’s stock, valued at $406,630. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,440 shares of company stock worth $1,193,831. Insiders own 33.70% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.